Literature DB >> 4001730

Methods of assessing the impact of congenital rubella infection.

W A Orenstein, S R Preblud, K J Bart, A R Hinman.   

Abstract

Monitoring of congenital rubella infection (CRI) involves measuring the assessable outcomes of infection of the pregnant woman. These assessable outcomes are infection itself, therapeutic abortion, and birth of infants with congenital rubella syndrome (CRS). The incidence of infections can be estimated with use of data on age-specific occurrence of acquired rubella or acquisition of antibody in females and on fertility rates. The incidence of CRS can be estimated from data on infections of pregnant women and reports in the literature of incidence rates of CRS among infants born of infected mothers. Surveillance of CRS can involve individual case detection or serosurveys among populations with defects characteristic of CRS, such as deafness, and among comparison groups. To assess the impact of CRI, countries without rubella control programs should estimate the frequency of infections in pregnant women from existing surveillance data or determine by serosurveys the susceptibility and/or age-specific acquisition of rubella antibody in postpubertal females. Countries with rubella control programs should monitor cases of acquired rubella and/or prevalence of seropositivity in postpubertal females, therapeutic abortions, and CRS to assess effectiveness of the program and to determine high-risk populations that should be targets of intense vaccination programs.

Entities:  

Mesh:

Year:  1985        PMID: 4001730     DOI: 10.1093/clinids/7.supplement_1.s22

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  8 in total

1.  Identification of Serologic Markers for School-Aged Children With Congenital Rubella Syndrome.

Authors:  Terri B Hyde; Helena Keico Sato; LiJuan Hao; Brendan Flannery; Qi Zheng; Kathleen Wannemuehler; Flávia Helena Ciccone; Heloisa de Sousa Marques; Lily Yin Weckx; Marco Aurélio Sáfadi; Eliane de Oliveira Moraes; Marisa Mussi Pinhata; Jaime Olbrich Neto; Maria Cecilia Bevilacqua; Alfredo Tabith Junior; Tatiana Alves Monteiro; Cristina Adelaide Figueiredo; Jon K Andrus; Susan E Reef; Cristiana M Toscano; Carlos Castillo-Solorzano; Joseph P Icenogle
Journal:  J Infect Dis       Date:  2014-10-31       Impact factor: 5.226

2.  Unseen blindness, unheard deafness, and unrecorded death and disability: congenital rubella in Kumasi, Ghana.

Authors:  J E Lawn; S Reef; B Baffoe-Bonnie; S Adadevoh; E O Caul; G E Griffin
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

3.  Incidence of congenital rubella syndrome in 19 regions of Europe in 1980-1986.

Authors:  I De la Mata; P De Wals; H Dolk; M F Lechat; R Beckers; I Borlee; F Lys; R Zori; J Goujard; C Stoll
Journal:  Eur J Epidemiol       Date:  1989-03       Impact factor: 8.082

Review 4.  Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review.

Authors:  T Panagiotopoulos; I Antoniadou; E Valassi-Adam
Journal:  BMJ       Date:  1999-12-04

Review 5.  Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 1: Burden of disease from CRS.

Authors:  F T Cutts; S E Robertson; J L Diaz-Ortega; R Samuel
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

6.  Evaluation of rubella screening in pregnant women.

Authors:  T W Gyorkos; T N Tannenbaum; M Abrahamowicz; G Delage; J Carsley; S Marchand
Journal:  CMAJ       Date:  1998-11-03       Impact factor: 8.262

7.  Comparison of a whole-virus enzyme immunoassay (EIA) with a peptide-based EIA for detecting rubella virus immunoglobulin G antibodies following rubella vaccination.

Authors:  M Zrein; J H Joncas; L Pedneault; L Robillard; R J Dwyer; M Lacroix
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

8.  Congenital rubella syndrome: pattern and presentation in a southern Nigerian tertiary hospital.

Authors:  Innocent Ocheyana George; Angela Ine Frank-Briggs; Raphael Sonny Oruamabo
Journal:  World J Pediatr       Date:  2009-11-13       Impact factor: 9.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.